Immunitybio Inc (IBRX)
ImmunityBio Inc (NASDAQ-IBRX) is a Healthcare biotechnology company, and its listed security is common stock on the NASDAQ exchange. The shares represent common equity in the business rather than a separate fund, bond, or depositary receipt. ImmunityBio develops biologic and immune-based medicines, with work centered on therapies and research programs for cancer and infectious diseases. Its activities are tied to the broader biotechnology sector, where companies typically rely on scientific development and regulatory progress. As a NASDAQ-listed common stock, IBRX reflects ownership interest in the company and trades in the public equity market.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IBRX
|
$7.49
|
-19.4% Downside
|
Overvalued
|
$12.75
|
37.2% Upside
|
Undervalued
|
Good
|
0.0%
|
November 5, 2026
|
54.0x
|
9.846 B
|
9.828 B
|
12.1%
|
38.4%
|
-7.6
|
29.0%
|
